Moderna’s phase-1 trials show experimental coronavirus vaccine can induce immune response

Moderna's COVID-19 vaccine has shown promising results by triggering an immune response in all volunteers during preliminary testing. The mRNA in the vaccine instructs body cells to produce proteins that mimic the coronavirus spike proteins, helping the immune system recognize and combat the virus. The phase 1 trial involved three groups with varying dosages, and those receiving two doses showed higher antibody levels than recovered COVID-19 patients. However, some volunteers experienced severe side effects, including high fever and nausea.

What was the outcome of Moderna's vaccine in preliminary testing?

• It failed to trigger an immune response.

• It caused severe side effects in all participants.

• It triggered an immune response in all volunteers.

• It was not tested on humans.

How does the mRNA in Moderna's vaccine work?

• It replaces the virus in the body.

• It creates antibodies immediately.

• It directly attacks the virus.

• It instructs cells to produce proteins similar to the virus.

What is the purpose of the proteins produced by the body after the vaccine is administered?

• To mimic the virus's spike proteins for immune recognition.

• To replace the virus in the body.

• To destroy the virus immediately.

• To cause a fever.

What was observed in participants who received two doses of the vaccine?

• They experienced no side effects.

• They showed no immune response.

• They had higher antibody levels than the average recovered patient.

• They had lower antibody levels than recovered patients.

What side effects were reported by some volunteers on the highest dosage?

• Mild headaches and fatigue.

• Severe fever, chills, headaches, or nausea.

• Increased energy levels.

• No side effects at all.